{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:08:18Z","timestamp":1782907698082,"version":"3.54.5"},"reference-count":78,"publisher":"Tech Science Press","issue":"5","license":[{"start":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T00:00:00Z","timestamp":1675468800000},"content-version":"vor","delay-in-days":399,"URL":"https:\/\/doi.org\/10.32604\/TSP-CROSSMARKPOLICY"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.32604\/or.2022.026913","type":"journal-article","created":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T18:28:05Z","timestamp":1675448885000},"page":"211-219","update-policy":"https:\/\/doi.org\/10.32604\/tsp-crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Histone deacetylase inhibitors as a novel therapeutic approach for pheochromocytomas and paragangliomas"],"prefix":"10.32604","volume":"30","author":[{"given":"ASPASIA","family":"MANTA","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SPYRIDON","family":"KAZANAS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"STEFANOS","family":"KARAMAROUDIS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HELEN","family":"GOGAS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DIMITRIOS","family":"C. ZIOGAS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"17807","reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: An endocrine society clinical practice guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-16-0467","article-title":"Management of adrenal incidentalomas: European society of endocrinology clinical practice guideline in collaboration with the European network for the study of adrenal tumors","volume":"175","author":"Fassnacht","year":"2016","journal-title":"European Journal of Endocrinology"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1245\/s10434-020-08221-2","article-title":"Update on pheochromocytoma and paraganglioma from the SSO endocrine and head and neck disease site working group, part 2 of 2: Perioperative management and outcomes of pheochromocytoma and paraganglioma","volume":"27","author":"Patel","year":"2020","journal-title":"Annals of Surgical Oncology"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-16-0033","article-title":"European society of endocrinology clinical practice guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma","volume":"174","author":"Plouin","year":"2016","journal-title":"European Journal of Endocrinology"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s12022-017-9484-5","article-title":"Update on adrenal tumours in 2017 world health organization (WHO) of endocrine tumours","volume":"28","author":"Lam","year":"2017","journal-title":"Endocrine Pathology"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1055\/s-0031-1301302","article-title":"An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes","volume":"44","author":"Gimenez-Roqueplo","year":"2012","journal-title":"Hormone and Metabolic Research"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1007\/s00261-019-02044-w","article-title":"Genetics and imaging of pheochromocytomas and paragangliomas: Current update","volume":"45","author":"Katabathina","year":"2020","journal-title":"Abdominal Radiology"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1093\/oxfordjournals.aje.a113947","article-title":"Biochemical screening for pheochromocytoma. Superiority of urinary metanephrines measurements","volume":"120","author":"Manu","year":"1984","journal-title":"American Journal of Epidemiology"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"4757","DOI":"10.1210\/jc.2009-1248","article-title":"Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma","volume":"94","author":"Timmers","year":"2009","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.3892\/etm.2018.5871","article-title":"Current diagnostic imaging of pheochromocytomas and implications for therapeutic strategy (Review)","volume":"15","author":"\u010ctvrtl\u00edk","year":"2018","journal-title":"Experimental and Therapeutic Medicine"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/cen.12341","article-title":"(131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: Systematic review and meta-analysis","volume":"80","author":"van Hulsteijn","year":"2014","journal-title":"Clinical Endocrinology"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2967\/jnumed.118.217463","article-title":"Efficacy and safety of high-specific-activity 131I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma","volume":"60","author":"Pryma","year":"2019","journal-title":"Journal of Nuclear Medicine"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/CCO.0000000000000589","article-title":"Malignant pheochromocytoma and paraganglioma: Management options","volume":"32","author":"Corssmit","year":"2020","journal-title":"Current Opinion in Oncology"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"267","DOI":"10.7326\/0003-4819-109-4-267","article-title":"Malignant pheochromocytoma: Effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine","volume":"109","author":"Averbuch","year":"1988","journal-title":"Annals of Internal Medicine"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s12672-013-0133-2","article-title":"Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine in patients with malignant pheochromocytoma and paraganglioma","volume":"4","author":"Tanabe","year":"2013","journal-title":"Hormones and Cancer"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"4040","DOI":"10.1210\/jc.2012-2356","article-title":"Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas","volume":"97","author":"Ayala-Ramirez","year":"2012","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/jso.24553","article-title":"Peptide receptor radionuclide treatment and (131)I-MIBG in the management of patients with metastatic\/progressive phaeochromocytomas and paragangliomas","volume":"115","author":"Nastos","year":"2017","journal-title":"Journal of Surgical Oncology"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"436","DOI":"10.3390\/cancers11040436","article-title":"Pheochromocytomas and paragangliomas: From genetic diversity to targeted therapies","volume":"11","author":"Pang","year":"2019","journal-title":"Cancers"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1093\/bfgp\/ell028","article-title":"Histone acetylation in gene regulation","volume":"5","author":"Verdone","year":"2006","journal-title":"Briefings in Functional Genomics and Proteomics"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/sj.embor.7400146","article-title":"Structures of protein domains that create or recognize histone modifications","volume":"5","author":"Bottomley","year":"2004","journal-title":"EMBO Reports"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/nrg2485","article-title":"The many roles of histone deacetylases in development and physiology: Implications for disease and therapy","volume":"10","author":"Haberland","year":"2009","journal-title":"Nature Reviews Genetics"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s40264-018-0773-9","article-title":"Safety and tolerability of histone deacetylase (HDAC) inhibitors in oncology","volume":"42","author":"Shah","year":"2019","journal-title":"Drug Safety"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"731","DOI":"10.3390\/nu10060731","article-title":"Targeting histone deacetylases with natural and synthetic agents: An emerging anticancer strategy","volume":"10","author":"Singh","year":"2018","journal-title":"Nutrients"},{"key":"ref24","first-page":"166","article-title":"Histone deacetylase inhibitors: Molecular mechanisms of action and clinical trials as anti-cancer drugs","volume":"3","author":"Kim","year":"2011","journal-title":"American Journal of Translational Research"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"4577","DOI":"10.1111\/bcp.14889","article-title":"Recent developments of HDAC inhibitors: Emerging indications and novel molecules","volume":"87","author":"Bondarev","year":"2021","journal-title":"British Journal of Clinical Pharmacology"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1042\/bj20021321","article-title":"Histone deacetylases (HDACs): Characterization of the classical HDAC family","volume":"370","author":"de Ruijter","year":"2003","journal-title":"Biochemical Journal"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"4273","DOI":"10.3390\/nu6104273","article-title":"The role of dietary histone deacetylases (HDACs) inhibitors in health and disease","volume":"6","author":"Bassett","year":"2014","journal-title":"Nutrients"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"15119","DOI":"10.3390\/ijms232315119","article-title":"Sirtuins (SIRTs) as a novel target in gastric cancer","volume":"23","author":"Poniewierska-Baran","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.3390\/ijms18071414","article-title":"Histone deacetylase inhibitors as anticancer drugs","volume":"18","author":"Eckschlager","year":"2017","journal-title":"International Journal of Molecular Sciences"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s10565-016-9347-8","article-title":"Histone deacetylase inhibitor induces cell apoptosis and cycle arrest in lung cancer cells via mitochondrial injury and p53 up-acetylation","volume":"32","author":"Bao","year":"2016","journal-title":"Cell Biology and Toxicology"},{"key":"ref31","unstructured":"ClinicalTrials.gov. NIH U.S. National Library of Medicine."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/bjc.2016.36","article-title":"Inhibition of histone deacetylases in cancer therapy: Lessons from leukaemia","volume":"114","author":"Ceccacci","year":"2016","journal-title":"British Journal of Cancer"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"184154","DOI":"10.1155\/2012\/184154","article-title":"Histone deacetylase inhibitors in cell pluripotency, differentiation, and reprogramming","volume":"2012","author":"Kretsovali","year":"2012","journal-title":"Stem Cells International"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1634\/theoncologist.2011-0031","article-title":"A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma","volume":"16","author":"Mohammed","year":"2011","journal-title":"The Oncologist"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/ANNONC\/MDV066","article-title":"Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation","volume":"26","author":"Fu","year":"2015","journal-title":"Annals of Oncology"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"3923","DOI":"10.1200\/JCO.2005.14.167","article-title":"Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer","volume":"23","author":"Kelly","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1158\/1078-0432.CCR-14-3240","article-title":"Phase I study of vorinostat as a radiation sensitizer with 131I-metaiodobenzylguanidine (131I-MIBG) for patients with relapsed or refractory neuroblastoma","volume":"21","author":"DuBois","year":"2015","journal-title":"Clinical Cancer Research"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1089\/CBR.2020.4633","article-title":"Potential for increasing uptake of radiolabeled 68Ga-DOTATOC and 123I-MIBG in patients with midgut neuroendocrine tumors using a histone deacetylase inhibitor vorinostat","volume":"36","author":"Pollard","year":"2021","journal-title":"Cancer Biotherapy & Radiopharmaceuticals"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.1200\/JCO.21.00703","article-title":"Randomized phase II trial of MIBG versus MIBG, vincristine, and irinotecan versus MIBG and vorinostat for patients with relapsed or refractory neuroblastoma: A report from NANT consortium","volume":"39","author":"DuBois","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1097\/CAD.0000000000000596","article-title":"Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung","volume":"29","author":"Balasubramaniam","year":"2018","journal-title":"Anti-Cancer Drugs"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1634\/theoncologist.2016-0060","article-title":"A phase II trial of a histone deacetylase inhibitor panobinostat in patients with low-grade neuroendocrine tumors","volume":"21","author":"Jin","year":"2016","journal-title":"The Oncologist"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"695","DOI":"10.2165\/00023210-200216100-00004","article-title":"Pharmacological and therapeutic properties of valproate: A summary after 35 years of clinical experience","volume":"16","author":"Perucca","year":"2002","journal-title":"CNS Drugs"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"291","DOI":"10.2478\/acph-2020-0021","article-title":"Anticonvulsant valproic acid and other short-chain fatty acids as novel anticancer therapeutics: Possibilities and challenges","volume":"70","author":"Lipska","year":"2020","journal-title":"Acta Pharmaceutica"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ctrv.2007.11.003","article-title":"Valproic acid as epigenetic cancer drug: Preclinical, clinical and transcriptional effects on solid tumors","volume":"34","author":"Duenas-Gonzalez","year":"2008","journal-title":"Cancer Treatment Reviews"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.surg.2008.08.027","article-title":"Histone deacetylase inhibitors upregulate Notch-1 and inhibit growth in pheochromocytoma cells","volume":"144","author":"Adler","year":"2008","journal-title":"Surgery"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"5188","DOI":"10.1158\/1078-0432.CCR-11-2258","article-title":"Molecular pathways: Context-dependent approaches to Notch targeting as cancer therapy","volume":"18","author":"Egloff","year":"2012","journal-title":"Clinical Cancer Research"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1186\/1471-2407-10-383","article-title":"Cell type-specific anti-cancer properties of valproic acid: independent effects on HDAC activity and Erk1\/2 phosphorylation","volume":"10","author":"Gotfryd","year":"2010","journal-title":"BMC Cancer"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/NBT1272","article-title":"Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug","volume":"25","author":"Marks","year":"2007","journal-title":"Nature Biotechnology"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1038\/sj.bjc.6603463","article-title":"Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor","volume":"95","author":"Richon","year":"2006","journal-title":"British Journal of Cancer"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","article-title":"FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma","volume":"12","author":"Mann","year":"2007","journal-title":"The Oncologist"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"e90458","DOI":"10.1371\/JOURNAL.PONE.0090458","article-title":"High-throughput screening for the identification of new therapeutic options for metastatic pheochromocytoma and paraganglioma","volume":"9","author":"Giubellino","year":"2014","journal-title":"PLoS One"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1056\/NEJMOA020152","article-title":"Germ-line mutations in nonsyndromic pheochromocytoma","volume":"346","author":"Neumann","year":"2002","journal-title":"The New England Journal of Medicine"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"8812","DOI":"10.1200\/JCO.2005.03.1484","article-title":"Genetic testing in pheochromocytoma or functional paraganglioma","volume":"23","author":"Amar","year":"2005","journal-title":"Journal of Clinical Oncology,"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"4506","DOI":"10.1096\/FJ.12-210146","article-title":"Missense mutations in the human SDHB gene increase protein degradation without altering intrinsic enzymatic function","volume":"26","author":"Yang","year":"2012","journal-title":"FASEB Journal"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3390\/PH12040180","article-title":"Metabolism and pharmacokinetic study of the boron-containing prodrug of belinostat (ZL277), a pan HDAC inhibitor with enhanced bioavailability","volume":"12","author":"Zhang","year":"2019","journal-title":"Pharmaceuticals"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/0165-3806(87)90096-4","article-title":"Differentiation of PC12 pheochromocytoma cells by sodium butyrate","volume":"428","author":"Byrd","year":"1987","journal-title":"Brain Research"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/0092-8674(78)90306-9","article-title":"The effect of sodium butyrate on histone modification","volume":"14","author":"Sealy","year":"1978","journal-title":"Cell"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"6235","DOI":"10.1007\/S11033-011-1443-5","article-title":"Dual effects of sodium butyrate on hepatocellular carcinoma cells","volume":"39","author":"Jiang","year":"2012","journal-title":"Molecular Biology Reports"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"2485S","DOI":"10.1093\/JN\/133.7.2485S","article-title":"Inhibition of histone deacetylase activity by butyrate","volume":"133","author":"Davie","year":"2003","journal-title":"The Journal of Nutrition"},{"key":"ref60","first-page":"178","article-title":"Sodium butyrate activates Notch1 signaling, reduces tumor markers, and induces cell cycle arrest and apoptosis in pheochromocytoma","volume":"1","author":"Cayo","year":"2009","journal-title":"American Journal of Translational Research"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7164\/ANTIBIOTICS.29.1","article-title":"A new antifungal antibiotic, trichostatin","volume":"29","author":"Tsuji","year":"1976","journal-title":"The Journal of Antibiotics"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1073\/pnas.98.1.87","article-title":"Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin","volume":"98","author":"Furumai","year":"2001","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"17174","DOI":"10.1016\/S0021-9258(17)44885-X","article-title":"Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A","volume":"265","author":"Yoshida","year":"1990","journal-title":"The Journal of Biological Chemistry"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.2174\/0929867043365099","article-title":"Trichostatin A-like hydroxamate histone deacetylase inhibitors as therapeutic agents: Toxicological point of view","volume":"11","author":"Vanhaecke","year":"2004","journal-title":"Current Medicinal Chemistry"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1677\/ERC-10-0090","volume":"18","author":"Martiniova","year":"2011","journal-title":"Endocrine-Related Cancer"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"301","DOI":"10.7164\/ANTIBIOTICS.47.301","article-title":"FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity","volume":"47","author":"Ueda","year":"1994","journal-title":"The Journal of Antibiotics"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1006\/EXCR.1998.4027","article-title":"FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor","volume":"241","author":"Nakajima","year":"1998","journal-title":"Experimental Cell Research"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0304-3835(03)00184-8","volume":"195","author":"Sasakawa","year":"2003","journal-title":"Cancer Letters"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1007\/S11605-007-0249-1","article-title":"Suberoyl bishydroxamic acid inhibits cellular proliferation by inducing cell cycle arrest in carcinoid cancer cells","volume":"11","author":"Greenblatt","year":"2007","journal-title":"Journal of Gastrointestinal Surgery"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1634\/THEONCOLOGIST.2007-0190","article-title":"Suberoyl bis-hydroxamic acid activates Notch-1 signaling and induces apoptosis in medullary thyroid carcinoma cells","volume":"13","author":"Ning","year":"2008","journal-title":"The Oncologist"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1245\/S10434-008-0194-6","article-title":"Combination therapy with histone deacetylase inhibitors and lithium chloride: A novel treatment for carcinoid tumors","volume":"16","author":"Adler","year":"2009","journal-title":"Annals of Surgical Oncology"},{"key":"ref72","first-page":"7563","article-title":"Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines","volume":"63","author":"Fang","year":"2003","journal-title":"Cancer Research"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"821082","DOI":"10.1155\/2013\/821082","article-title":"Plant polyphenols and oxidative metabolites of the herbal alkenylbenzene methyleugenol suppress histone deacetylase activity in human colon carcinoma cells","volume":"2013","author":"Groh","year":"2013","journal-title":"Journal of Nutrition and Metabolism"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3892\/IJO.2012.1449","article-title":"Green tea polyphenols increase p53 transcriptional activity and acetylation by suppressing class I histone deacetylases","volume":"41","author":"Thakur","year":"2012","journal-title":"International Journal of Oncology"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1007\/s12032-014-0390-0","article-title":"(-)-Epigallocatechin-3-gallate induces cancer cell apoptosis via acetylation of amyloid precursor protein","volume":"32","author":"Hu","year":"2015","journal-title":"Medical Oncology"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"10678","DOI":"10.1074\/JBC.M109.057836","article-title":"Histone deacetylase inhibitor valproic acid inhibits cancer cell proliferation via down-regulation of the alzheimer amyloid precursor protein","volume":"285","author":"Venkataramani","year":"2010","journal-title":"The Journal of Biological Chemistry"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.canlet.2009.02.019","article-title":"Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges","volume":"280","author":"Atadja","year":"2009","journal-title":"Cancer Letters"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/7131802","article-title":"Efficacy of panobinostat for the treatment of multiple myeloma","volume":"2020","author":"Eleutherakis-Papaiakovou","year":"2020","journal-title":"Journal of Oncology"}],"container-title":["Oncology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.techscience.com\/files\/or\/2022\/TSP_OR-30-5\/OncolRes-30-05-26913\/OncolRes-30-26913.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T21:59:31Z","timestamp":1733522371000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.techscience.com\/or\/v30n5\/51413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":78,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.32604\/or.2022.026913","relation":{},"ISSN":["0965-0407"],"issn-type":[{"value":"0965-0407","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"2022-10-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-03","order":2,"name":"published","label":"Published Online","group":{"name":"publication_history","label":"Publication History"}}]}}